Market Context — Why This Technology, Why Now

Rising R&D costs and the imperative for more effective, safer therapies are pushing pharmaceutical companies to adopt advanced drug delivery systems. Regulatory bodies are also increasingly scrutinizing drug safety profiles, making highly targeted solutions critical. This technology aligns with the global shift towards precision medicine, offering a competitive edge by enabling the development of therapies with superior efficacy and reduced toxicity, thereby meeting both market demand and regulatory expectations.

Key Competitive Advantages
01

Reduces Side Effects Through High Target Specificity: Achieves precise binding to specific target cells by presenting nucleic acid aptamers on its surface, significantly suppressing off-target effects of drugs.

02

Offers Diverse Nucleic Acid Aptamer Options: Utilizes a variety of nucleic acid aptamers over 40 nucleotides in length, expanding applicability to a wide range of diseases and targets.

03

Streamlines Manufacturing Through Self-Assembly: Forms through the self-assembly of multiple subunits, reducing manufacturing costs and simplifying scale-up compared to complex conventional synthesis processes.

Market Opportunity
Oncology (Cancer Treatment)
$5.5B globally (AI est.)
The demand for precision medicine is rapidly increasing, aiming to maximize the therapeutic effects of anticancer drugs while reducing side effects through cancer cell-specific targeting.
Pharmaceutical companies developing oncology drugs Biotech firms specializing in targeted therapies Contract Research Organizations (CROs) for cancer research
Gene Therapy and Nucleic Acid Drugs
$2.5B globally (AI est.)
Efficient and safe delivery of genes and nucleic acids into cells is crucial for the success of gene therapies, accelerating the development of new treatment methods.
Gene therapy developers Biotech companies focused on RNA therapeutics Specialty pharma firms in rare diseases
Diagnostic Agents and Biosensors
$2B globally (AI est.)
Application to highly sensitive diagnostic agents and biosensors targeting specific disease markers could improve the accuracy of early diagnosis and disease monitoring.
Medical device manufacturers Diagnostic kit developers Clinical laboratory solution providers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent, granted after rigorous examination and successful amendments against a rejection, establishes a broad and robust scope of protection. It covers the artificial viral capsid's components, manufacturing methods, and various applications across 8 claims. This history indicates a stable patent less susceptible to invalidation, providing licensees with confidence for business development.

Competitive White Space

Adjacent white space exists in novel aptamer discovery methods, advanced manufacturing scale-up techniques beyond self-assembly, and integration with specific diagnostic imaging or therapeutic devices not directly covered by the capsid's delivery mechanism.

Economic Impact
~$6.5M/year estimated drug development cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assumes an adopting company develops 5 new drug candidates annually in preclinical stages. This technology could improve target specificity, reducing preclinical failure rates by ~20% (AI est.). With a preclinical development cost of ~$6.5M/candidate (AI est.), the potential annual savings are 5 candidates × ~$6.5M/candidate × 20% reduction = ~$6.5M (AI est.).

Speed to Market
3× faster than in-house development
This technology is based on nucleic acid aptamer design algorithms and viral capsid self-assembly principles, demonstrating high compatibility with existing biomolecule synthesis and nanoparticle manufacturing techniques. This significantly reduces the time required for basic research and mechanism elucidation compared to de novo development, enabling rapid prototype creation and evaluation. The combination of known elemental technologies facilitates a swift transition to development phases post-adoption.
Competitive Positioning

X: Targeting Specificity & Precision
Y: Development Cost Efficiency

Business Models & Applications
🤝 Joint Research & Development Model
Combines the licensee's drug candidates with this technology to co-develop new therapeutics. Shares development risks and profits to accelerate market entry.
🔑 Platform Licensing
Licenses the drug delivery platform technology for specific disease areas or drug classes. Enables licensees to strengthen their in-house development pipelines.
🧪 Contract Development & Manufacturing Services
Provides design and manufacturing services for artificial viral capsids targeting specific molecules on a contract basis. Offers high-performance drug delivery systems to third parties.
Adjacent Application Opportunities
🔬 Diagnostics & Testing
High-Sensitivity Pathogen Detection Kits
Leveraging the specific binding capability of nucleic acid aptamers, this technology could be applied as a diagnostic probe to efficiently capture pathogens or disease markers. Developing rapid, high-sensitivity detection kits by presenting specific pathogen aptamers on the surface of artificial viral capsids is a potential application.
🌾 Agriculture & Plant Protection
Targeted Pesticide Delivery for Plant Diseases
By designing nucleic acid aptamers that target specific plant pathogens or pests and loading them onto artificial viral capsids, an environmentally friendly, selective pesticide delivery system could be developed. This is expected to reduce pesticide application volumes and maximize efficacy, contributing to sustainable agriculture.
🧪 Materials Science
Functional Nanomaterials & Biointerfaces
Self-assembling artificial viral capsids, as nanoparticles with uniform size and surface structure, could be applied to functional material development. They have potential as new high-performance materials in biointerface technologies, such as foundational materials for biosensors or scaffold materials for cell culture.
Integration Roadmap — Estimated 22-Month Deployment
Phase 1: Technology Evaluation & Initial Design
Duration: 4 months
Evaluates the fundamental principles of this technology and its compatibility with the licensee's target diseases and drug candidates. Involves selecting nucleic acid aptamers and performing initial capsid structure design.
Phase 2: Prototype Development & In Vitro/In Vivo Evaluation
Duration: 9 months
Synthesizes an artificial viral capsid prototype based on the design and evaluates target binding, cellular uptake efficiency, and drug release characteristics in vitro. Conducts in vivo proof-of-concept studies in animal models as needed.
Phase 3: Preclinical Development Planning & Scale-Up Review
Duration: 9 months
Based on evaluation results, formulates a preclinical development plan using the optimized capsid. Initiates reviews for manufacturing process scale-up potential and quality control system establishment.
Technical Feasibility
This technology is based on the principle that multiple subunits self-assemble to form functional capsids. This indicates high compatibility with existing biomolecule synthesis and nanoparticle manufacturing technologies, suggesting a relatively easy path to prototype construction. The conjugation of nucleic acid aptamers is also achievable through established chemical synthesis methods, leading to a low technical barrier for adoption.
Success Scenario
Adopting this technology could accelerate the development of next-generation therapeutics that specifically deliver drugs to target disease cells. This has the potential to maximize drug efficacy while significantly reducing side effects, leading to a dramatic improvement in patient quality of life. Consequently, it is estimated that clinical trial success rates could increase, shortening time-to-market for new drugs and contributing to a notable increase in annual revenue.
Patent Record
APPLICATION NO.
特願2021-079799
REGISTRATION NO.
7697656
FILING DATE
2021/05/10
GRANT DATE
2025/06/16
EXPIRATION DATE
2041/05/10
PATENT HOLDER
国立大学法人鳥取大学
Examination History
2024年04月08日
出願審査請求書
2025年03月18日
拒絶理由通知書
2025年05月12日
手続補正書（自発・内容）
2025年05月12日
意見書
2025年05月27日
特許査定